StreetInsider.com News Articles

Form 8-K Rein Therapeutics, Inc. For: Jul 20

Tue, 21 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260721/26795703.html

Form 8-K Rein Therapeutics, Inc. For: Jul 20

Tue, 21 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260721/26795703.html

Rein Therapeutics expands Phase 2 IPF trial to all five countries

Tue, 21 Jul 2026 08:01:01 -0400

Rein Therapeutics (NASDAQ: RNTX) announced that its Phase 2 RENEW clinical trial is now enrolling patients across all five planned countries, following the addition of Germany to existing sites in the United States, United Kingdom, Australia, and Poland.

The RENEW study is a randomized, placebo-controlled trial evaluating inhaled LTI-03 in approximately 120 patients with idiopathic pulmonary fibrosis (IPF). Patients will be randomized to receive one of two dose levels of LTI-03 or a placebo. The primary efficacy endpoint is the change from baseline in forced vital capacity, a measure of lung function.

The company said the expansion increases the number of active

Rein Therapeutics expands Phase 2 IPF trial to all five countries

Tue, 21 Jul 2026 08:01:01 -0400

The company said the expansion increases the number of active

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Tue, 21 Jul 2026 08:00:00 -0400

Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary Fibrosis
Company on track to report initial topline data in 2H 2026

AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced that its Phase 2 RENEW clinical trial is now open and enrolling patients across all five planned countries, with Germany joining the United States, United Kingdom, Australia, and Poland.

The RENEW study

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Tue, 21 Jul 2026 08:00:00 -0400

Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary Fibrosis
Company on track to report initial topline data in 2H 2026

The RENEW study

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Tue, 21 Jul 2026 08:00:00 -0400

Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary Fibrosis
Company on track to report initial topline data in 2H 2026

The RENEW study

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Tue, 21 Jul 2026 08:00:00 -0400

Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary Fibrosis
Company on track to report initial topline data in 2H 2026

The RENEW study

Maxim Group Starts Rein Therapeutics (RNTX) at Buy

Mon, 20 Jul 2026 07:33:42 -0400

Maxim Group analyst Jason McCarthy initiates coverage on Rein Therapeutics (NASDAQ: RNTX) with a Buy rating and a price target of $4.00.

For an analyst ratings summary and ratings history on Rein Therapeutics click here. For more ratings news on Rein Therapeutics click here.

Shares of Rein Therapeutics closed at $0.86 yesterday.

Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: Voss Capital, LP

Tue, 14 Jul 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260714/26769385.html

Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: Voss Capital, LP

Tue, 14 Jul 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260714/26769385.html

Rein Therapeutics expands Phase 2 trial to UK, enrolls 16 patients

Thu, 11 Jun 2026 08:02:13 -0400

Rein Therapeutics Inc. (NASDAQ: RNTX) announced the first patient has been randomized in the United Kingdom as part of its Phase 2 RENEW clinical trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis.

The company has enrolled 16 patients to date in the trial. Clinical trial sites are currently enrolling patients in the United States, Australia, and the United Kingdom. Additional sites in two more countries are expected to begin enrollment in the coming months.

"We are pleased to see continued enrollment momentum in our trial and the activation of additional international sites," said Brian Windsor, Chief Executive Officer of Rein Therapeutics.

Rein Therapeutics expands Phase 2 trial to UK, enrolls 16 patients

Thu, 11 Jun 2026 08:02:13 -0400

"We are pleased to see continued enrollment momentum in our trial and the activation of additional international sites," said Brian Windsor, Chief Executive Officer of Rein Therapeutics.

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Thu, 11 Jun 2026 08:00:00 -0400

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)
First patient randomized in the United Kingdom
Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom
Two additional countries expected to be added in the coming months

AUSTIN, Texas, June 11, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2 RENEW clinical

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Thu, 11 Jun 2026 08:00:00 -0400

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)
First patient randomized in the United Kingdom
Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom
Two additional countries expected to be added in the coming months

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Thu, 11 Jun 2026 08:00:00 -0400

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)
First patient randomized in the United Kingdom
Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom
Two additional countries expected to be added in the coming months

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Thu, 11 Jun 2026 08:00:00 -0400

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)
First patient randomized in the United Kingdom
Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom
Two additional countries expected to be added in the coming months

Form DEFA14A Rein Therapeutics, Inc.

Mon, 08 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26615220.html

Form DEFA14A Rein Therapeutics, Inc.

Mon, 08 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26615220.html

Form ARS Rein Therapeutics, Inc. For: Dec 31

Mon, 08 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26615221.html

Form ARS Rein Therapeutics, Inc. For: Dec 31

Mon, 08 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26615221.html

Form DEF 14A Rein Therapeutics, Inc. For: Jul 20

Mon, 08 Jun 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260608/26615219.html

Form DEF 14A Rein Therapeutics, Inc. For: Jul 20

Mon, 08 Jun 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260608/26615219.html

Rein Therapeutics (RNTX) PT Lowered to $8 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:38 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Brandon Folkes lowered the price target on Rein Therapeutics (NASDAQ: RNTX) to $8.00 (from $10.00) while maintaining a Buy rating.

The analyst commented: "RNTX reported a meaningful set of 1Q26 updates, with the most important development being the post-quarter $57.5M common-stock financing, which we believe materially changes the stock setup by removing the largest overhang on the story and funding the ongoing RENEW Phase 2 trial of LTI-03 in IPF through completion. The regulatory overhang had already largely cleared with the FDA allowing the Phase 2 program to resume and the

Rein Therapeutics (RNTX) PT Lowered to $8 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:38 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Brandon Folkes lowered the price target on Rein Therapeutics (NASDAQ: RNTX) to $8.00 (from $10.00) while maintaining a Buy rating.